Trial Profile
A Phase IV, Open Label, Multi-center Study to Assess the Effect of Intravitreal Injections of Macugen (Pegaptanib Sodium Injection) Administered Every 6 Weeks for 48 Weeks on the Corneal Endothelium.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Jan 2021
Price :
$35
*
At a glance
- Drugs Pegaptanib (Primary)
- Indications Diabetic macular oedema; Retinal vein occlusion; Wet age-related macular degeneration
- Focus Therapeutic Use
- Sponsors Bausch & Lomb; Bausch Health Companies
- 22 Nov 2019 Status changed from active, no longer recruiting to completed.
- 02 Oct 2019 Planned End Date changed from 1 Nov 2020 to 30 Nov 2020.
- 21 Nov 2018 Planned End Date changed from 1 Jun 2018 to 1 Nov 2020.